Digital health company DarioHealth Corp (NASDAQ:DRIO) said on Thursday that it has secured a clinical study contract for its B2B diabetes platform.
The company has signed the agreement with an undisclosed pharmaceutical company that is seeking US FDA clearance for a new drug related to managing diabetes. DarioHealth will run and track the blood glucose readings of participants in the clinical study via its B2B diabetes platform.
DarioHealth's B2B platform aims to increase user engagement during the course of the clinical study and will leverage key learnings from its direct-to-consumer success, including allowing the participants to log their BGM readings in real-time in the Dario logbook and utilise the reminders and statistics features.
This move into clinical studies and clinician practices shows the adoption of Dario Blood Glucose Monitoring System products and solutions going beyond the scope of just the consumer.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes